Concurrent Session: How to optimize toxicity and relapse control after HCT
Saturday, September 9, 2023 08:00 AM - 09:00 AM
Grand Ballroom J-K
Chair
Jaap Jan Boelens, MD, PhD, Transplantation and Cellular Therapies, MSKCC, USA
Speakers
Alexandre Troullioud Lucas, MD, MSc, Memorial Sloan Kettering Cancer Center, USA – The Impact of Immune Reconstitution after HCT on Toxicity and Relapse
Shabi Soheili, PhD, Smart Immune, France – ProTcell Technology: Increasing the benefit/risk ratio of allo HSCT
Andromachi Scaradavou, MD, Memorial Sloan Kettering Cancer Center, USA – Second Hematopoietic Cell Transplants with Unrelated Cord Blood Grafts for Post-Transplant Relapse in Pediatric Patients
Immune reconstitution after HCT is driver of outcomes. Strategies (incl. cellular) to improve / better predict this will be discussed; PKPD and tools to better predict IR, pro-thymocytes infusion, donor cell source (Cord blood / UM171 CB) impacts disease/infection control.
Session Objectives
Jaap Jan Boelens, MD, PhD, Transplantation and Cellular Therapies, MSKCC, USA
Speakers
Alexandre Troullioud Lucas, MD, MSc, Memorial Sloan Kettering Cancer Center, USA – The Impact of Immune Reconstitution after HCT on Toxicity and Relapse
Shabi Soheili, PhD, Smart Immune, France – ProTcell Technology: Increasing the benefit/risk ratio of allo HSCT
Andromachi Scaradavou, MD, Memorial Sloan Kettering Cancer Center, USA – Second Hematopoietic Cell Transplants with Unrelated Cord Blood Grafts for Post-Transplant Relapse in Pediatric Patients
Immune reconstitution after HCT is driver of outcomes. Strategies (incl. cellular) to improve / better predict this will be discussed; PKPD and tools to better predict IR, pro-thymocytes infusion, donor cell source (Cord blood / UM171 CB) impacts disease/infection control.
Session Objectives
- Preparative regimen can be individualized to better predict the immune reconstitution after transplantation.
- The thymic reconstitution may be expedited with cell therapies
- Cord blood cells may have unique features to control leukemia and viral disease
Jaap Jan Boelens MD, PhD
Pediatric-Oncologist, Chief
Transplantation and Cellular Therapies, MSKCC
Chair
Pediatric-Oncologist, Chief
Transplantation and Cellular Therapies, MSKCC
Chair
Andromachi Scaradavou MD
Pediatric Hematologist-Oncologist
Memorial Sloan Kettering Cancer Center
Speaker
Pediatric Hematologist-Oncologist
Memorial Sloan Kettering Cancer Center
Speaker
Alexandre Troullioud Lucas MD, MSc
Pediatric Hematologist-Oncologist
Memorial Sloan Kettering Cancer Center
Speaker
Pediatric Hematologist-Oncologist
Memorial Sloan Kettering Cancer Center
Speaker